Group 1 - The upcoming National Day and Mid-Autumn Festival holiday is expected to see increased travel, necessitating health and safety precautions for travelers [1] - The transition between seasons is a peak period for respiratory diseases, highlighting the importance of personal protective measures such as wearing masks and maintaining hand hygiene in crowded places [2] - Recommendations for managing common ailments like flu and cold include using medications containing acetaminophen for fever and pain relief, and specific cold medications for symptoms like sneezing and nasal congestion [2] Group 2 - Travelers prone to motion sickness should prepare motion sickness medication in advance, with specific guidelines for usage timing and caution regarding children's medication [3] - In case of injuries during travel, it is advised to carry antiseptic supplies and band-aids, and to seek medical attention for serious injuries while applying ice for swelling [4] - Attention to food safety is crucial during the holiday, with recommendations to avoid undercooked foods and to be cautious with food storage and consumption [6][7]

Core Viewpoint - Berberine shows potential as a long-term preventive agent for colorectal adenoma recurrence after polypectomy, with significant reductions in recurrence and neoplasm occurrence rates observed in clinical studies [4][6][8]. Group 1: Study Findings - A recent study indicated that berberine treatment resulted in a lower adenoma recurrence rate of 34.7% compared to 52.1% in the control group, and a lower tumor occurrence rate of 63.4% versus 71.0% after a follow-up period of at least 6 years [4][7]. - In a previous two-year randomized clinical trial, berberine significantly reduced the recurrence rate of colorectal adenomas to 36% compared to 47% in the placebo group, with no serious adverse events reported [6][9]. - The long-term protective effect of berberine was confirmed in a retrospective cohort study that followed up on participants from the initial trial, demonstrating sustained benefits post-treatment [7][8]. Group 2: Research Background - The study on berberine was conducted by a team from Shanghai Jiao Tong University School of Medicine and published in Cell Reports Medicine, extending the follow-up of a prior clinical trial [4][6]. - The initial trial involved 895 patients, with 781 participants recruited for the follow-up study, which assessed the long-term effects of berberine on adenoma recurrence [7][8].

Group 1: Investor Relations Activities - The company held a performance briefing for the 2024 annual report on April 29, 2025, via online communication [4] - Participants included the chairman, general manager, board secretary, financial officer, and sponsor representative [4] Group 2: Market Expansion and Product Certification - The company has obtained the EU export certification for its products, which requires compliance with the European Pharmacopoeia (CEP) and on-site inspections [5] - The company aims to enhance its competitiveness in the EU market by improving production quality and collaborating with EU clients [5] Group 3: Revenue Composition and Market Share - The company's revenue is primarily derived from pharmaceutical raw materials, food additives, cosmetics, and health products [6] - The European market accounts for approximately 40% of exports, while the US, Japan, Australia, and Canada account for about 60% [6] - The NHDC product has captured over 27% of the company's main business revenue in the domestic food additive market [6] Group 4: Growth Drivers and Strategic Focus - Future growth in the plant extract industry is driven by increasing consumer health awareness and advancements in extraction technology [8] - The company plans to deepen its focus on both domestic and international markets, particularly in food additives and pharmaceutical raw materials [9] Group 5: Financial Performance and Profit Margins - The company's revenue increased by 27.78% year-on-year in 2024, attributed to the successful implementation of its strategic plan [7] - The overall gross margin for products increased in 2024, but is expected to decline in 2025 due to rising costs and market competition [10] Group 6: Production and R&D Updates - The company is currently optimizing production processes and has completed 11 R&D projects in 2024 [15] - The new production lines are expected to be fully operational by mid-2025, which will enhance production capacity [14] Group 7: Market Trends and Future Outlook - The company anticipates a gradual recovery in gross margins as production lines stabilize and international trade conditions improve [12][13] - The market for Vitamin P products is expected to grow significantly due to rising health consciousness and expanding application areas [17]